BioLineRx

BLRX

Biotechnology · Healthcare

Price

$2.83

-0.07 (-2.41%)

Market Cap

$12.3M

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count falling — buybacks

−90.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 44.2M (2021) → 4.1M (2025)

BioLineRx is a small Israeli biotechnology company that develops drugs to treat cancer and other serious diseases. Its main approved product is Motixafortide (sold as Aphexda), which is used to help cancer patients collect stem cells before a bone marrow transplant. The company focuses on oncology, meaning treatments related to cancer, and partners with larger pharmaceutical companies to help sell its medicines.

BioLineRx makes money by selling Aphexda in the United States through a commercial partnership with Sun Pharmaceutical Industries, earning revenue from product sales and potentially from licensing deals. The company is headquartered in Israel but generates most of its commercial revenue in the U.S. market. It is a very small company with a market cap near zero, and it spends far more money than it earns, which is reflected in its deeply negative operating margin. The key risk is whether Aphexda can gain enough market adoption to generate sufficient revenue before the company needs to raise additional cash.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+87.1% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-999.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$8M/ year

↓ Declining (-16% vs prior year)

643.9% of revenue

35.8x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

4.3%ownership

Relatively low insider ownership

Cash Runway

~23 months

$17M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

Revenue accelerating

BioLineRx grew revenue 87% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

80.1%

Premium pricing power — 80.1% gross margin

Operating Margin

-629.8%

Losing money on operations — -629.8%

ROCE

-12.3%

Weak — -12.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-93.7%

Shrinking sales (-93.7% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-557.5%

Burning cash (-557.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.47

Conservative — low debt load (0.47)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial